EP3525754A1 - Method for producing dermatological and cosmetic preparations - Google Patents
Method for producing dermatological and cosmetic preparationsInfo
- Publication number
- EP3525754A1 EP3525754A1 EP17798315.2A EP17798315A EP3525754A1 EP 3525754 A1 EP3525754 A1 EP 3525754A1 EP 17798315 A EP17798315 A EP 17798315A EP 3525754 A1 EP3525754 A1 EP 3525754A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- proportion
- added
- ultrasonic waves
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Definitions
- the present invention relates to a process for the preparation of dermatological and cosmetic preparations with pronounced lamellar structures using hydrogenated phosphatidylcholine.
- DMS Dermata Membrane Structure
- the lamellar structures correspond to the skin physiology and serve the skin to protect against the ingress of external substances and regulate the transepidermal water loss through the skin.
- lamellar structures The formation of the lamellar structures is dependent on the geometric packing factors, such as the volume of the fatty acid chains, the critical chain length, and area occupied by the headgroup (Israelachvili, JN In Intermolecular and Surface Forces, 2nd Ed., Jovanovich, HB; London 1994). This means that not every amphiphilic substance can form lamellar structures or membranes.
- the best-known lipid capable of forming such lamellar structures is phosphatidylcholine (PC), also part of human cell membranes. Phosphatidylcholine is found in a high concentration in soya lecithin.
- phosphatidylcholine especially the hydrogenated one, shows a pronounced barrier-stabilizing effect.
- the skin barrier is stabilized by PCH-containing preparations with lamellar structure in such a way that after application of the transepidermal water loss (TEWL) changes only slightly when external substances act on the skin.
- TEWL transepidermal water loss
- the protection thus obtained is also characterized by a high water resistance and welding strength.
- the use of hydrogenated phosphatidylcholine is highly desirable for cosmetic or dermatological preparations.
- the object of this invention was to develop a method with which it is possible, using the known since 1995 ingredients for membrane structure creams, in particular using hydrogenated phosphatidylcholine, stable cream bases for topical application to produce a qualitatively and quantitatively pronounced lamellar Have structure and in which active ingredients and biological materials at room temperature, in one operation open-minded (ie detached from their cells and agglomerates split) and can be stored directly between the forming lamellar structures.
- Another important advantage of the inventive production process is the possibility of producing very small units of 20-50 ml with individual formulations adapted to the skin type.
- Galenic preparations for cosmetic or dermatological products consist predominantly of a water phase and a fat phase. Both phases are usually mixed or emulsified with the aid of appropriate emulsifiers and with the use of high-speed stirrers, mixers or the like.
- the inner phase is distributed as finely as possible in the outer phase, so that a sufficient stability and storage time is achieved.
- a sufficient amount of emulsifiers and preservatives is also necessary to ensure a practical storage time of the products.
- Emulsifiers and preservatives are, however, substances which pollute the skin and are often triggers of allergies.
- a cosmetic or dermatological preparation can be produced in less than one minute, without chemical emulsifiers and at room temperature, even using temperature-sensitive, biological materials .
- preemulsions can also be used, which are then mixed in a second step at any later time with additional dermatological and / or cosmetic agents, for example with biological cell materials, blood components such as blood plasma or blood serum, vegetable oils, vitamins, peptides , Hyaluronic acids, plant extracts, fruit acids and the like.
- the ultrasound introduction described above can already take place during the production of the pre-emulsion and / or after the addition of the additives in a second operation.
- the introduction of the ultrasound in the pre-emulsion has the purpose of hydrogenating with the aid of the present Membraniipide, preferably phosphatidylcholine and / or not hydrogenated to produce fine oil droplets in the range of 5-500nm, preferably in a size of 50-250 nm, which then in the described second step, in the introduction of the additives, form particularly fine lamellar layers.
- the aid of the present Membraniipide preferably phosphatidylcholine and / or not hydrogenated to produce fine oil droplets in the range of 5-500nm, preferably in a size of 50-250 nm, which then in the described second step, in the introduction of the additives, form particularly fine lamellar layers.
- the monohydric and / or polyhydric alcohols are preferably methyl, ethyl, propyl or isopropyl alcohol, phenoxyethanol, pentylene, butylene or hexylene glycol. definitions
- Ultrasound machines are available in different designs and services.
- devices are needed which provide sufficient energy needed to disperse a liquid phase (fat phase) into small drops in a second phase (stable phase).
- imploding cavitation bubbles cause intense shockwaves in the liquid and as a result, generate very high velocity liquid jets.
- the newly formed droplets of the dispersed phase align themselves immediately with the help of the membrane lipids and form lamellar structures with a thickness of a few nanometers, with the lipophilic phases and the hydrophilic phases then alternatingly stacking up.
- the vibration amplitudes of the introduced ultrasound preferably move from about 1 to 200 microns, while the high pressure and low pressure cycles between 15,000-30,000 cycles / sec, preferably at 20,000 cycles / sec. be.
- the shear forces mechanically close the cell envelope and thereby increase the exchange of material.
- the membrane lipids hydrogenated phosphatidylcholine
- the lamellar layers in which the intracellular material is spontaneously incorporated are formed.
- Organic cell material in this patent means materials which have been dissolved out of biological cells. These may be of plant origin, e.g. Algae and / or animal or human origin. They may be derived from tissues and / or body fluids such as blood and / or from microorganisms such as yeasts or bacteria.
- MS concentrate prepared with hydrogenated phosphatidylcholine, neutral oil and homogenized via a high-pressure homogenizer
- neutral oil medium-chain triglycerides
- the components are placed in a glass container, which is closed and placed in the ultrasound machine, which introduces the ultrasound from the outside through the wall. After just one minute, the formation of a homogeneous cream mass is evident.
- the components are placed in a glass container, which is closed and placed in the ultrasound machine, which introduces the ultrasound from the outside through the wall. After just one minute, the formation of a homogeneous cream mass is evident.
- the components of the pre-emulsion are heated to 70 ° C and charged with ultrasound until a homogeneous milk is formed with a droplet size of 50-200 nm.
- This pre-emulsion can be stored under exclusion of air for several months.
- the components are mixed, resulting in the formation of fine, lamellar layer structures directly from the nanoparticles of the pre-emulsion, which is indicated by a significant increase in viscosity, while the added active ingredients, such as oils, blood components and hyaluronic acid intercalate between the lamellar layers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH01356/16A CH713023A2 (en) | 2016-10-11 | 2016-10-11 | Process for the preparation of dermatological and cosmetic preparations with pronounced lamellar structures using phosphatidylcholine and biological cell materials, which are disrupted by the action of ultrasonic waves and at the same time embedded between the lamellar structures. |
PCT/IB2017/056221 WO2018069814A1 (en) | 2016-10-11 | 2017-10-09 | Method for producing dermatological and cosmetic preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3525754A1 true EP3525754A1 (en) | 2019-08-21 |
Family
ID=60331675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17798315.2A Pending EP3525754A1 (en) | 2016-10-11 | 2017-10-09 | Method for producing dermatological and cosmetic preparations |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3525754A1 (en) |
CH (1) | CH713023A2 (en) |
WO (1) | WO2018069814A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH714305B1 (en) * | 2017-11-06 | 2022-07-15 | Cosmetolab Ag | Process for preparing topical formulations and prepared formulations. |
WO2020033712A1 (en) | 2018-08-08 | 2020-02-13 | Sobel Brands, LLC | Cosmetic base compositions and associated cosmetic compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4221255C2 (en) * | 1992-06-26 | 1994-09-15 | Lancaster Group Ag | Cosmetolipid-containing cosmetic |
DE4327679A1 (en) * | 1993-08-13 | 1995-02-16 | Lancaster Group Ag | Functional oxygenated preparation |
DE4447287C1 (en) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Droplet-in-fluid composition to transport agent e.g. through skin |
DE19857492A1 (en) | 1998-12-14 | 2000-06-15 | Hans Lautenschlaeger | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
DE10108097A1 (en) | 2000-02-25 | 2001-09-13 | Kuhs Kosmetik Gmbh & Co Kg | Cosmetic formulation, especially for use on aging and/or stressed skin, contains trimethylammonium-methyl compound, metabolite and/or S-adenosylmethionine besides water and substance forming lamellar structures with water |
DE102005011786A1 (en) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Process for preparing ultrafine submicron suspensions |
DE102006015544A1 (en) | 2006-03-31 | 2007-10-04 | Kuhs Gmbh | Topical composition, useful for infants or baby e.g. to reduce skin roughness, comprises hydrophilic liquid, anti-inflammatory active agent and a carrier substance with hydrophilic liquid forming lamellar double-membrane layer |
EP2020221B1 (en) * | 2007-06-19 | 2012-02-29 | Neubourg Skin Care GmbH & Co. KG | DMS (Derma Membrane Structure) in foaming creams |
PL2363108T3 (en) * | 2010-03-02 | 2018-04-30 | Neubourg Skin Care Gmbh & Co. Kg | Foam formulation containing at least one triterpenoid |
DE102011110749A1 (en) | 2011-08-16 | 2013-02-21 | Gabriele Blume | Cosmetic or pharmaceutical composition with lamellar structures using sucrose fatty triesters - simple and easy preparation |
-
2016
- 2016-10-11 CH CH01356/16A patent/CH713023A2/en not_active Application Discontinuation
-
2017
- 2017-10-09 WO PCT/IB2017/056221 patent/WO2018069814A1/en unknown
- 2017-10-09 EP EP17798315.2A patent/EP3525754A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CH713023A2 (en) | 2018-04-13 |
WO2018069814A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2661108C2 (en) | Use of a liposome dispersion in cosmetics | |
EP2020221B1 (en) | DMS (Derma Membrane Structure) in foaming creams | |
DE3125710C2 (en) | ||
DE60130719T2 (en) | Foaming cosmetic cream for the treatment of oily skin | |
EP2363108B1 (en) | Foam formulation containing at least one triterpenoid | |
EP1937224A2 (en) | Skincare products | |
WO2008138894A2 (en) | Surfactant-free foam formulations | |
DE3537723A1 (en) | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL USE THAT CONTAINS NIOSOME AND AT LEAST A WATER-SOLUBLE POLYAMIDE, AND METHOD FOR PRODUCING THIS COMPOSITION | |
DE3713494A1 (en) | METHOD FOR PRODUCING A DISPERSION OF LIPID BALLS IN AN AQUEOUS PHASE AND DISPERSIONS AVAILABLE ACCORDING TO THIS METHOD | |
DE69828596T2 (en) | WAESSERIGE COMPOSITIONS CONTAINING A LIPIDIC AND A TENSID ON LANOLINBASIS AND ITS USE | |
DE4021082A1 (en) | Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s) | |
DE102006015544A1 (en) | Topical composition, useful for infants or baby e.g. to reduce skin roughness, comprises hydrophilic liquid, anti-inflammatory active agent and a carrier substance with hydrophilic liquid forming lamellar double-membrane layer | |
EP0945136B9 (en) | Topical pharmaceutical preparation comprising ciclosporin | |
WO2012146576A1 (en) | Oil-in-water emulsion concentrate, method for producing same, and skin cosmetic containing said oil-in-water emulsion concentrate | |
WO2018069814A1 (en) | Method for producing dermatological and cosmetic preparations | |
WO2017063748A1 (en) | Composition and method for producing dermatological and cosmetic preparations having pronounced lamellar structures using phosphatidycholine and fermentation by microorganisms | |
DE3815473A1 (en) | System of active substances for lipid exchange with target structures | |
JPS5939338A (en) | Emulsified composition | |
KR102199766B1 (en) | Manufacturing method of multi-lamellar structured transparent liquid crystal composition | |
DE4310015A1 (en) | Composition for care of the human skin | |
DE10015463B4 (en) | Cream in the form of an overbased water-in-oil emulsion | |
CH714305A2 (en) | Process for the preparation of topical formulations and prepared formulations. | |
EP2768471B1 (en) | Aqueous dispersion having a content of lipid nanoparticles, process for production thereof and use thereof | |
AT361896B (en) | BALL DISPERSION AND METHOD FOR THE PRODUCTION THEREOF | |
DE19635359C2 (en) | Lotion for body care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190507 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200608 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MAUSER, JOHANNES ALOIS Owner name: KUHS, BERND ARIS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KUHS, BERND ARIS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |